Vir/GSK Move Lead Coronavirus Antibody Into Phase III
Safety In 20 Phase II Patients Enabled Testing In 1,300 People
Executive Summary
Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.
You may also be interested in...
How Much Should Governments Pay For COVID-19 Monoclonal Antibody Therapies?
US government’s $450m manufacturing commitment for Regeneron’s antibody cocktail and Gilead’s price for remdesivir drive lower expectations on pricing for the antibody treatments, especially since it seems likely there could be several competing products.
How Much Should Governments Pay For COVID-19 Monoclonal Antibody Therapies?
US government’s $450m manufacturing commitment for Regeneron’s antibody cocktail and Gilead’s price for remdesivir drive lower expectations on pricing for the antibody treatments, especially since it seems likely there could be several competing products.
Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?
Data from the first 275 patients in the trial are promising, but outside experts say they are wary of another hasty Emergency Use Authorization.
Need a specific report? 1000+ reports available
Buy Reports